Nictur (Desmopressin Acetate)

Desmopressin mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers insertion of aquaporin‑2 channels, allowing more water to be reabsorbed and urine to become concentrated. It also stimulates endothelial cells to release von Willebrand factor and factor VIII, improving haemostasis.

The exact dose of Nictur is determined by the prescribing clinician based on the patient’s age, weight, renal function, and the specific indication. Healthcare professionals tailor the regimen to achieve the desired therapeutic effect while minimizing the risk of adverse events.

Safety data for desmopressin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after a careful risk‑benefit assessment.

To request Nictur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

Nictur (desmopressin) is a synthetic vasopressin analogue with high selectivity for V2 receptors, offering a longer half‑life and fewer vasoconstrictive effects than natural vasopressin. Compared with other antidiuretic drugs, it provides more predictable water‑reabsorption and is also effective in certain bleeding disorders, making it a versatile therapeutic option.

Nictur should be stored at ambient temperature, below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Nictur is taken orally, usually as a tablet, with or without water as directed by the prescriber. The exact timing (e.g., before bedtime for nocturnal enuresis) and any fluid‑restriction instructions are individualized based on the indication and patient response.

The most serious risks include severe hyponatremia, which can lead to seizures or coma, and water intoxication causing cerebral edema. Patients should be monitored for rapid weight gain, confusion, headache, or nausea, and serum sodium levels should be checked regularly during therapy.

Nictur is contraindicated in individuals with known hypersensitivity to desmopressin or any of its excipients, and in patients with uncontrolled hyponatremia or severe renal impairment where water balance cannot be safely managed. Clinicians must evaluate each patient’s medical history before initiating therapy.